Format

Send to

Choose Destination
Stem Cell Investig. 2019 Feb 25;6:6. doi: 10.21037/sci.2019.02.03. eCollection 2019.

The past, present, and future of CRM1/XPO1 inhibitors.

Author information

1
Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, Chicago, IL, USA.

Abstract

Therapies targeted at inhibiting nucleo-cytoplasmic transport have found broad applications in the field of oncology. Chromosome region maintenance 1 (CRM1), better known as exportin 1 (XPO1), is the protein transporter responsible for the nucleo-cytoplasmic shuttling of most of the tumor suppressor proteins (TSP) and growth regulatory factors. XPO1 is also upregulated in many malignancies and associated with a poor prognosis. Its inhibition has been a target of therapy, and hence, the selective inhibitors of nuclear transport (SINE) compounds were developed as a novel class of anti-cancer agents. The most well-known SINE agent is selinexor (KPT-330) and has been widely tested in phase I and II clinical trials in both solid tumors and hematologic malignancies. This review discusses how dysregulation of XPO1 promotes tumorigenesis, the historical considerations in the development of SINE compounds, and their role in current clinical therapies.

KEYWORDS:

Selinexor; chromosome region maintenance 1/exportin 1 inhibitors (XPO1/CRM1 inhibitors)

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Publication type

Publication type

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center